4-aminopyridine has been researched along with Chronic Disease in 27 studies
Chronic Disease: Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Systemic administration of pilocarpine to adult rats induces an acute status epilepticus followed by spontaneous recurrent seizures after a 1-2-week silent period." | 7.69 | Interictal discharges in the hippocampus of rats with long-term pilocarpine seizures. ( Avoli, M; Gloor, P; Nagao, T, 1994) |
| " The effects of selective block of I(Kur) by low concentrations of 4-aminopyridine or the biphenyl derivative AVE 0118 were investigated on right atrial action potentials (APs) in trabeculae from patients in sinus rhythm (SR) or chronic atrial fibrillation (AF)." | 3.72 | Role of IKur in controlling action potential shape and contractility in the human atrium: influence of chronic atrial fibrillation. ( Christ, T; Dobrev, D; Hála, O; Heubach, JF; Knaut, M; Ravens, U; Varró, A; Wettwer, E, 2004) |
| "Systemic administration of pilocarpine to adult rats induces an acute status epilepticus followed by spontaneous recurrent seizures after a 1-2-week silent period." | 3.69 | Interictal discharges in the hippocampus of rats with long-term pilocarpine seizures. ( Avoli, M; Gloor, P; Nagao, T, 1994) |
| " Fourteen (56%) patients had 26 adverse reactions." | 2.71 | Efficacy and safety of 4-aminopyridine in patients with long-term spinal cord injury: a randomized, double-blind, placebo-controlled trial. ( Arenas-Hernández, R; Castañeda-Hernández, G; Grijalva, I; Guízar-Sahagún, G; Ibarra, A; Maldonado-Julián, H; Mino, D; Salgado-Ceballos, H; Serra, O; Vidal-Cantú, G, 2003) |
| " Safety assessments: physical examinations, vital sign measurements, clinical laboratory tests, electrocardiogram recordings, and adverse events." | 2.71 | Pharmacokinetics and safety of multiple oral doses of sustained-release 4-aminopyridine (Fampridine-SR) in subjects with chronic, incomplete spinal cord injury. ( Blight, AR; Cohen, R; Hayes, KC; Hsieh, JT; Katz, MA; Potter, PJ, 2004) |
| " A statistically significant difference in the initial rate and extent of absorption, but not in total 4-AP bioavailability over the 12-hour study period, was evident between tetraplegic patients, 0." | 2.69 | Absorption characteristics of sustained-release 4-aminopyridine (fampridine SR) in patients with chronic spinal cord injury. ( Brunnemann, SR; Hayes, KC; Hsieh, JT; Mason, D; Pathak, MS; Potter, PJ; Segal, JL; Tierney, DS, 2000) |
| "Following animal mode studies to establish dosing safety, six subjects with chronic SCI were examined." | 2.69 | Intrathecal administration of 4-aminopyridine in chronic spinal injured patients. ( Blight, AR; Calvillo, O; Donovan, WH; Halter, JA, 2000) |
| " The dose-response characteristics of acutely and chronically injured axons were compared." | 1.30 | Conduction block in acute and chronic spinal cord injury: different dose-response characteristics for reversal by 4-aminopyridine. ( Blight, AR; Kelly, TM; Shi, R, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (3.70) | 18.7374 |
| 1990's | 10 (37.04) | 18.2507 |
| 2000's | 11 (40.74) | 29.6817 |
| 2010's | 4 (14.81) | 24.3611 |
| 2020's | 1 (3.70) | 2.80 |
| Authors | Studies |
|---|---|
| Villasana-Salazar, B | 1 |
| Hernández-Soto, R | 1 |
| Guerrero-Gómez, ME | 1 |
| Ordaz, B | 1 |
| Manrique-Maldonado, G | 1 |
| Salgado-Puga, K | 1 |
| Peña-Ortega, F | 1 |
| Giordano, I | 1 |
| Bogdanow, M | 1 |
| Jacobi, H | 1 |
| Jahn, K | 1 |
| Minnerop, M | 1 |
| Schoels, L | 1 |
| Synofzik, M | 1 |
| Teufel, J | 1 |
| Klockgether, T | 1 |
| Simpson, DM | 1 |
| Goldenberg, J | 1 |
| Kasner, S | 1 |
| Nash, M | 1 |
| Reding, MJ | 1 |
| Zweifler, RM | 1 |
| Suarez, G | 1 |
| Zhao, P | 1 |
| Henney, HR | 1 |
| Rabinowicz, AL | 1 |
| Carrazana, E | 1 |
| Serafini, R | 1 |
| Dettloff, S | 1 |
| Loeb, JA | 1 |
| Hu, XQ | 1 |
| Xiao, D | 1 |
| Zhu, R | 1 |
| Huang, X | 1 |
| Yang, S | 1 |
| Wilson, SM | 1 |
| Zhang, L | 1 |
| Grijalva, I | 1 |
| Guízar-Sahagún, G | 1 |
| Castañeda-Hernández, G | 1 |
| Mino, D | 1 |
| Maldonado-Julián, H | 1 |
| Vidal-Cantú, G | 1 |
| Ibarra, A | 1 |
| Serra, O | 1 |
| Salgado-Ceballos, H | 1 |
| Arenas-Hernández, R | 1 |
| Hayes, KC | 3 |
| Potter, PJ | 3 |
| Hsieh, JT | 3 |
| Katz, MA | 1 |
| Blight, AR | 8 |
| Cohen, R | 2 |
| Wettwer, E | 1 |
| Hála, O | 1 |
| Christ, T | 1 |
| Heubach, JF | 1 |
| Dobrev, D | 1 |
| Knaut, M | 1 |
| Varró, A | 1 |
| Ravens, U | 1 |
| Boërio, D | 1 |
| Lefaucheur, JP | 1 |
| Hogrel, JY | 1 |
| Créange, A | 1 |
| Cardenas, DD | 1 |
| Ditunno, J | 1 |
| Graziani, V | 1 |
| Jackson, AB | 1 |
| Lammertse, D | 1 |
| Potter, P | 1 |
| Sipski, M | 1 |
| Russell, JW | 1 |
| Windebank, AJ | 1 |
| Harper, CM | 1 |
| Mubagwa, K | 1 |
| Flameng, W | 1 |
| Carmeliet, E | 1 |
| Nagao, T | 1 |
| Avoli, M | 1 |
| Gloor, P | 1 |
| Smirnov, SV | 1 |
| Robertson, TP | 1 |
| Ward, JP | 1 |
| Aaronson, PI | 1 |
| Hansebout, RR | 1 |
| Fawcett, S | 1 |
| Reddy, K | 1 |
| Bergin, PS | 1 |
| Miller, DH | 1 |
| Hirsch, NP | 1 |
| Murray, NM | 1 |
| Allatt, RD | 1 |
| Wolfe, DL | 1 |
| Lam, S | 1 |
| Hamilton, JT | 1 |
| Shi, R | 1 |
| Kelly, TM | 1 |
| Haghighi, SS | 1 |
| Clapper, A | 1 |
| Johnson, GC | 1 |
| Stevens, A | 1 |
| Prapaisilp, A | 1 |
| Yoshimura, N | 1 |
| de Groat, WC | 1 |
| Segal, JL | 1 |
| Brunnemann, SR | 1 |
| Pathak, MS | 1 |
| Tierney, DS | 1 |
| Mason, D | 1 |
| Donovan, WH | 2 |
| Halter, JA | 2 |
| Graves, DE | 1 |
| Calvillo, O | 2 |
| McCann, MT | 1 |
| Sherwood, AM | 1 |
| Castillo, T | 1 |
| Parsons, KC | 1 |
| Strayer, JR | 1 |
| van der Bruggen, MA | 1 |
| Huisman, HB | 1 |
| Beckerman, H | 1 |
| Bertelsmann, FW | 1 |
| Polman, CH | 1 |
| Lankhorst, GJ | 1 |
| Workman, AJ | 1 |
| Kane, KA | 1 |
| Rankin, AC | 1 |
| Bonnet, S | 1 |
| Dubuis, E | 1 |
| Vandier, C | 1 |
| Martin, S | 1 |
| Marthan, R | 1 |
| Savineau, JP | 1 |
| Gruner, JA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Quality of Life, Efficacy and Safety of High Doses of 4-aminopyridine in Patients With Clinically Complete Chronic Spinal Cord Injury: Multicenter, Randomized, Double Blind, Placebo Controlled Clinical Trial[NCT03899584] | Phase 3 | 150 participants (Actual) | Interventional | 2019-07-17 | Active, not recruiting | ||
| Prevention of Recurrent Symptomatic Urinary Tract Infections in Participants With Chronic Neurogenic Bladder Dysfunction: A Mixed Method Study[NCT02591901] | Phase 2 | 48 participants (Actual) | Interventional | 2018-04-06 | Completed | ||
| A Single Dose Pharmaco-Diagnostic for Peripheral Nerve Continuity After Trauma[NCT04026568] | Phase 2/Phase 3 | 1 participants (Actual) | Interventional | 2021-08-17 | Terminated (stopped due to Study investigator left Institution) | ||
| Pharmaco-Diagnostic Crossover Trial for Peripheral Nerve Continuity After Trauma[NCT06003166] | Phase 3 | 68 participants (Anticipated) | Interventional | 2024-04-30 | Not yet recruiting | ||
| [NCT00004939] | Phase 3 | 34 participants | Interventional | 1996-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Return of lost sensation after nerve injury attributable to circulating 4-AP. Subjective return of sensation in the injured limb or portion of the limb.~Patients for this trial are not able to sense in portions of their limbs. The measure will be sensation, measured on the binary scale of yes or no (able to feel the extremity versus unable to feel) This is assessed through clinical examination of the injured limb." (NCT04026568)
Timeframe: During dosing of drug intervention (5 hours) and 2, 6, 9, 12, 15, 20 weeks post injury
| Intervention | participants (Number) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Return of sensation prior to administration of study drug-baseline | Return of sensation 1 hour post study drug administration | Return of sensation 2 hours post study drug administration | Return of sensation 3 hours post study drug administration | Return of sensation 4 hours post study drug administration | Return of sensation 5 hours post study drug administration | Return of sensation 2 weeks post injury | Return of sensation 6 weeks post injury | Return of sensation 9 weeks post injury | Return of sensation 12 weeks post injury | Return of sensation 15 weeks post injury | Return of sensation 18 weeks post injury | Return of sensation 20 weeks post injury | |
| Placebo | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | NA | NA | NA | NA |
1 review available for 4-aminopyridine and Chronic Disease
| Article | Year |
|---|---|
[Pathophysiology and treatment of fatigue in multiple sclerosis].
Topics: 4-Aminopyridine; Acute Disease; Amantadine; Amifampridine; Asthenia; Benzhydryl Compounds; Central N | 2006 |
10 trials available for 4-aminopyridine and Chronic Disease
| Article | Year |
|---|---|
Dalfampridine in chronic sensorimotor deficits after ischemic stroke: A proof of concept study.
Topics: 4-Aminopyridine; Adolescent; Adult; Aged; Aged, 80 and over; Chronic Disease; Cross-Over Studies; Do | 2015 |
Efficacy and safety of 4-aminopyridine in patients with long-term spinal cord injury: a randomized, double-blind, placebo-controlled trial.
Topics: 4-Aminopyridine; Administration, Oral; Adult; Chronic Disease; Dose-Response Relationship, Drug; Dou | 2003 |
Pharmacokinetics and safety of multiple oral doses of sustained-release 4-aminopyridine (Fampridine-SR) in subjects with chronic, incomplete spinal cord injury.
Topics: 4-Aminopyridine; Adolescent; Adult; Aged; Chronic Disease; Delayed-Action Preparations; Female; Huma | 2004 |
Phase 2 trial of sustained-release fampridine in chronic spinal cord injury.
Topics: 4-Aminopyridine; Adult; Aged; Chronic Disease; Delayed-Action Preparations; Dose-Response Relationsh | 2007 |
Phase 2 trial of sustained-release fampridine in chronic spinal cord injury.
Topics: 4-Aminopyridine; Adult; Aged; Chronic Disease; Delayed-Action Preparations; Dose-Response Relationsh | 2007 |
Phase 2 trial of sustained-release fampridine in chronic spinal cord injury.
Topics: 4-Aminopyridine; Adult; Aged; Chronic Disease; Delayed-Action Preparations; Dose-Response Relationsh | 2007 |
Phase 2 trial of sustained-release fampridine in chronic spinal cord injury.
Topics: 4-Aminopyridine; Adult; Aged; Chronic Disease; Delayed-Action Preparations; Dose-Response Relationsh | 2007 |
Phase 2 trial of sustained-release fampridine in chronic spinal cord injury.
Topics: 4-Aminopyridine; Adult; Aged; Chronic Disease; Delayed-Action Preparations; Dose-Response Relationsh | 2007 |
Phase 2 trial of sustained-release fampridine in chronic spinal cord injury.
Topics: 4-Aminopyridine; Adult; Aged; Chronic Disease; Delayed-Action Preparations; Dose-Response Relationsh | 2007 |
Phase 2 trial of sustained-release fampridine in chronic spinal cord injury.
Topics: 4-Aminopyridine; Adult; Aged; Chronic Disease; Delayed-Action Preparations; Dose-Response Relationsh | 2007 |
Phase 2 trial of sustained-release fampridine in chronic spinal cord injury.
Topics: 4-Aminopyridine; Adult; Aged; Chronic Disease; Delayed-Action Preparations; Dose-Response Relationsh | 2007 |
Phase 2 trial of sustained-release fampridine in chronic spinal cord injury.
Topics: 4-Aminopyridine; Adult; Aged; Chronic Disease; Delayed-Action Preparations; Dose-Response Relationsh | 2007 |
Phase 2 trial of sustained-release fampridine in chronic spinal cord injury.
Topics: 4-Aminopyridine; Adult; Aged; Chronic Disease; Delayed-Action Preparations; Dose-Response Relationsh | 2007 |
Phase 2 trial of sustained-release fampridine in chronic spinal cord injury.
Topics: 4-Aminopyridine; Adult; Aged; Chronic Disease; Delayed-Action Preparations; Dose-Response Relationsh | 2007 |
Phase 2 trial of sustained-release fampridine in chronic spinal cord injury.
Topics: 4-Aminopyridine; Adult; Aged; Chronic Disease; Delayed-Action Preparations; Dose-Response Relationsh | 2007 |
Phase 2 trial of sustained-release fampridine in chronic spinal cord injury.
Topics: 4-Aminopyridine; Adult; Aged; Chronic Disease; Delayed-Action Preparations; Dose-Response Relationsh | 2007 |
Phase 2 trial of sustained-release fampridine in chronic spinal cord injury.
Topics: 4-Aminopyridine; Adult; Aged; Chronic Disease; Delayed-Action Preparations; Dose-Response Relationsh | 2007 |
Phase 2 trial of sustained-release fampridine in chronic spinal cord injury.
Topics: 4-Aminopyridine; Adult; Aged; Chronic Disease; Delayed-Action Preparations; Dose-Response Relationsh | 2007 |
Phase 2 trial of sustained-release fampridine in chronic spinal cord injury.
Topics: 4-Aminopyridine; Adult; Aged; Chronic Disease; Delayed-Action Preparations; Dose-Response Relationsh | 2007 |
Treatment of stable chronic demyelinating polyneuropathy with 3,4-diaminopyridine.
Topics: 4-Aminopyridine; Action Potentials; Adult; Aged; Aged, 80 and over; Amifampridine; Charcot-Marie-Too | 1995 |
4-Aminopyridine in chronic spinal cord injury: a controlled, double-blind, crossover study in eight patients.
Topics: 4-Aminopyridine; Adolescent; Adult; Aged; Chronic Disease; Double-Blind Method; Electrophysiology; F | 1993 |
Absorption characteristics of sustained-release 4-aminopyridine (fampridine SR) in patients with chronic spinal cord injury.
Topics: 4-Aminopyridine; Absorption; Adult; Area Under Curve; Biological Availability; Chronic Disease; Cros | 2000 |
Intravenous infusion of 4-AP in chronic spinal cord injured subjects.
Topics: 4-Aminopyridine; Adult; Aged; Chronic Disease; Cross-Over Studies; Double-Blind Method; Electromyogr | 2000 |
Intrathecal administration of 4-aminopyridine in chronic spinal injured patients.
Topics: 4-Aminopyridine; Adult; Aged; Chronic Disease; Cross-Over Studies; Double-Blind Method; Female; Huma | 2000 |
Randomized trial of 4-aminopyridine in patients with chronic incomplete spinal cord injury.
Topics: 4-Aminopyridine; Adult; Aged; Chronic Disease; Cross-Over Studies; Double-Blind Method; Female; Huma | 2001 |
16 other studies available for 4-aminopyridine and Chronic Disease
| Article | Year |
|---|---|
Chronic intermittent hypoxia transiently increases hippocampal network activity in the gamma frequency band and 4-Aminopyridine-induced hyperexcitability in vitro.
Topics: 4-Aminopyridine; Animals; Chronic Disease; Gamma Rhythm; Hippocampus; Hypoxia, Brain; Male; Nerve Ne | 2020 |
Experience in a short-term trial with 4-aminopyridine in cerebellar ataxia.
Topics: 4-Aminopyridine; Cerebellar Ataxia; Chronic Disease; Disability Evaluation; Humans; Potassium Channe | 2013 |
Neocortical slices from adult chronic epileptic rats exhibit discharges of higher voltages and broader spread.
Topics: 4-Aminopyridine; Animals; Chronic Disease; Disease Models, Animal; Electrocorticography; Epilepsy; I | 2016 |
Chronic hypoxia suppresses pregnancy-induced upregulation of large-conductance Ca2+-activated K+ channel activity in uterine arteries.
Topics: 4-Aminopyridine; Acclimatization; Altitude; Animals; Blotting, Western; Cells, Cultured; Chronic Dis | 2012 |
Role of IKur in controlling action potential shape and contractility in the human atrium: influence of chronic atrial fibrillation.
Topics: 4-Aminopyridine; Action Potentials; Aged; Atrial Appendage; Atrial Fibrillation; Biphenyl Compounds; | 2004 |
Resting and action potentials of nonischemic and chronically ischemic human ventricular muscle.
Topics: 4-Aminopyridine; Action Potentials; Chronic Disease; Diacetyl; Epinephrine; Heart; Humans; In Vitro | 1994 |
Interictal discharges in the hippocampus of rats with long-term pilocarpine seizures.
Topics: 4-Aminopyridine; Animals; Chronic Disease; Electrophysiology; Evoked Potentials; Hippocampus; In Vit | 1994 |
Chronic hypoxia is associated with reduced delayed rectifier K+ current in rat pulmonary artery muscle cells.
Topics: 4-Aminopyridine; Animals; Chronic Disease; Electric Conductivity; Electrophysiology; Glyburide; Hypo | 1994 |
Failure of 3,4-diaminopyridine to reverse conduction block in inflammatory demyelinating neuropathies.
Topics: 4-Aminopyridine; Amifampridine; Chronic Disease; Demyelinating Diseases; Humans; Neural Conduction; | 1993 |
Preclinical trial of 4-aminopyridine in patients with chronic spinal cord injury.
Topics: 4-Aminopyridine; Adult; Blood Pressure; Body Temperature; Chronic Disease; Drug Evaluation; Electroe | 1993 |
Conduction block in acute and chronic spinal cord injury: different dose-response characteristics for reversal by 4-aminopyridine.
Topics: 4-Aminopyridine; Action Potentials; Acute Disease; Animals; Chronic Disease; Dose-Response Relations | 1997 |
Effect of 4-aminopyridine and single-dose methylprednisolone on functional recovery after a chronic spinal cord injury.
Topics: 4-Aminopyridine; Animals; Behavior, Animal; Chronic Disease; Glucocorticoids; Male; Methylprednisolo | 1998 |
Increased excitability of afferent neurons innervating rat urinary bladder after chronic bladder inflammation.
Topics: 4-Aminopyridine; Action Potentials; Animals; Chronic Disease; Cyclophosphamide; Cystitis; Female; Ga | 1999 |
The contribution of ionic currents to changes in refractoriness of human atrial myocytes associated with chronic atrial fibrillation.
Topics: 4-Aminopyridine; Action Potentials; Aged; Atrial Fibrillation; Atrial Function; Calcium Channel Bloc | 2001 |
Reversal of chronic hypoxia-induced alterations in pulmonary artery smooth muscle electromechanical coupling upon air breathing.
Topics: 4-Aminopyridine; Animals; Blood Pressure; Calcium; Cells, Cultured; Chronic Disease; Electrophysiolo | 2002 |
Augmentation by 4-aminopyridine of vestibulospinal free fall responses in chronic spinal-injured cats.
Topics: 4-Aminopyridine; Aminopyridines; Animals; Cats; Chronic Disease; Efferent Pathways; Electromyography | 1987 |